Case Studies in Initial HIV Management: When, What, and How
Release Date: October 21, 2022
Support for this activity has been made possible through educational grants from Gilead Sciences, Merck, Theratechnologies, and ViiV Healthcare.
Antiretroviral therapy should be initiated for all persons with HIV immediately after (or as soon as possible after) an HIV diagnosis. HIV treatment guidelines are frequently updated and discuss optimal strategies for initiating antiretroviral therapy. Despite this support, it can still be challenging for the care team to start antiretroviral medications in a timely manner and select an optimal regimen that considers a patient’s unique health characteristics and social situations. Using a combination of didactic presentation and case vignettes, this 1.0 hour free interactive CME/CNE-Certified webinar will review common situations clinicians might face when initiating antiretroviral therapy and will discuss team-based strategies to support patients starting antiretrovirals .
- Select a regimen that is appropriate for rapid start of antiretroviral therapy and describe optimal timing of rapid start.
- Compare guideline-recommended initial regimens’ potential impact on common chronic comorbidities such as cardiovascular disease, kidney disease, and diabetes.
- Identify two strategies that can be used by team members when initiating antiretroviral therapy in persons who have been inconsistent in follow up.
Jennifer Cocohoba, PharmD, MAS
Professor and Vice Chair for Faculty Development
Department of Clinical Pharmacy at University of California San Francisco
Karen Tashima, MD
Professor of Medicine, Director of Clinical Trials, The Miriam Hospital
Warren Alpert Medical School, Brown University
Jennifer Cocohoba, PharmD, MAS, is Professor of Clinical Pharmacy and Vice Chair for Faculty Development at the University of California, San Francisco School of Pharmacy, Department of Clinical Pharmacy. As a pharmacist for the UCSF Women’s HIV Program, she conducts medication consultations and leads quality assurance initiatives around prescribing. Her research interests focus on pharmacy-based interventions to improve adherence, medication use in people living with HIV, and sex differences in antiretroviral pharmacoepidemiology.
Karen Tashima, MD, is a Professor of Medicine in the Division of Infectious Diseases at The Warren Alpert Medical School of Brown University. She oversees the HIV Research Program at The Miriam Hospital Immunology Center. Dr. Tashima is also Chair of The Miriam Hospital’s IRB. Dr. Tashima was the chair of the ACTG OPTIONS study evaluating new regimens for patients with extensively drug-resistant HIV virus and is currently on the leadership team for the ACTG’s long-acting ARV study for patients with adherence challenges. She provides care to individuals living with HIV and other infectious diseases at The Miriam Hospital in Providence, RI and at Family Healthcare Center at SSTAR in Fall River, MA. She runs an active clinical trials program at The Miriam Hospital.
In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity..
Nurse Practitioners and Nurses
American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours
(1.0 Pharmacotherapeutic Contact Hours).
Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.0 contact hours.
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until October 21, 2023. PAs should only claim credit commensurate with the extent of their participation.
Other members of the care team will receive a certificate of participation.
This activity has been designed to meet the educational needs of the HIV care team, including physicians (both specialists and primary care/family medicine), nurses, nurse practitioners, physician assistants, and pharmacists who are in practice but are newer to HIV medicine or who are in training. Other healthcare providers may also participate.
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Jennifer Cocohoba, PharmD, MAS, discloses the following relevant financial relationships: Grant Support: ViiV Healthcare, Janssen, Genentech
Karen Tashima, MD, discloses the following relevant financial relationships: Grant/Research Support: Gilead Sciences, ViiV Healthcare
John JD Juchniewicz, MCIS, CHCP, FACEHP; Natalie Kirkwood, RN, BSN, JD; Edward Moylan RP; Daiquiri Y. Robinson: No relevant financial relationships to disclose.
This activity will not review off-label or investigational information.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or its ACTHIV Institute. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Instructions on How to Receive Credit
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CE credit for your participation, please complete the post-assessment and program evaluation. Your certificate will be available for printing immediately.
Privacy and Contact
This program should be viewed at a resolution of 1024 x 768 or higher using current versions of Microsoft Internet Explorer, Firefox, Chrome or Safari. A high-speed Internet connection is recommended.
© 2022. This accredited continuing education activity is held as copyrighted © by American Academy of CME. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).